Novo Nordisk's Wegovy Now Available in Daily Pill Form, Offering a New Alternative for Weight-Loss Treatment
In a significant development, Novo Nordisk has launched Wegovy, a GLP-1 weight-loss medication, in pill form. This advancement marks the first time a GLP-1 medication has been made available as a daily oral tablet, allowing users to transition away from weekly injections. The FDA-approved pills are now available for purchase at pharmacies with a prescription and will become stronger by the end of the week.
Wegovy's active ingredient, semaglutide, is identical to Ozempic's, while Mounjaro and Zepbound contain different components. Semaglutide mimics GLP-1, a hormone produced by the small intestine, which helps lower blood sugar levels and slow digestion. To take Wegovy pills, users must swallow them daily on an empty stomach with water and refrain from eating, drinking, or taking other medications for 30 minutes afterward.
A starter dose of 1.5mg is available now, with stronger doses expected to be released soon. Patients can increase their dosage every 30 days as needed until they reach the maximum level. Novo Nordisk's senior vice president, Ed Cinca, expressed excitement about the pill's launch, stating that it will empower more individuals to achieve weight-loss goals and lower cardiovascular disease risks.
The pill's price has been set at $25 per month for commercially-insured users through a savings program offered by Novo Nordisk. Out-of-pocket users can expect to pay around $149 per month for the 1.5mg and 4mg doses until April, when prices will increase to $199. A one-month supply of the higher doses costs $299.
The FDA approved Wegovy pills after a 64-week clinical trial involving 307 overweight or obese adults without diabetes. Participants who took the pill lost an average of 17% of their body weight and experienced reduced cardiovascular risks.
As Eli Lilly develops a similar pill, forglipron, it is expected to launch by this summer with less restrictive dosing. However, more data on clinical trials has yet to be released early this year, showing an average weight loss of 11% over 72 weeks at the highest dose.
In a significant development, Novo Nordisk has launched Wegovy, a GLP-1 weight-loss medication, in pill form. This advancement marks the first time a GLP-1 medication has been made available as a daily oral tablet, allowing users to transition away from weekly injections. The FDA-approved pills are now available for purchase at pharmacies with a prescription and will become stronger by the end of the week.
Wegovy's active ingredient, semaglutide, is identical to Ozempic's, while Mounjaro and Zepbound contain different components. Semaglutide mimics GLP-1, a hormone produced by the small intestine, which helps lower blood sugar levels and slow digestion. To take Wegovy pills, users must swallow them daily on an empty stomach with water and refrain from eating, drinking, or taking other medications for 30 minutes afterward.
A starter dose of 1.5mg is available now, with stronger doses expected to be released soon. Patients can increase their dosage every 30 days as needed until they reach the maximum level. Novo Nordisk's senior vice president, Ed Cinca, expressed excitement about the pill's launch, stating that it will empower more individuals to achieve weight-loss goals and lower cardiovascular disease risks.
The pill's price has been set at $25 per month for commercially-insured users through a savings program offered by Novo Nordisk. Out-of-pocket users can expect to pay around $149 per month for the 1.5mg and 4mg doses until April, when prices will increase to $199. A one-month supply of the higher doses costs $299.
The FDA approved Wegovy pills after a 64-week clinical trial involving 307 overweight or obese adults without diabetes. Participants who took the pill lost an average of 17% of their body weight and experienced reduced cardiovascular risks.
As Eli Lilly develops a similar pill, forglipron, it is expected to launch by this summer with less restrictive dosing. However, more data on clinical trials has yet to be released early this year, showing an average weight loss of 11% over 72 weeks at the highest dose.
! Novo Nordisk is raking it in while people are struggling to make ends meet. I'm all for innovation and progress, but let's not forget about those who need these meds the most. What about those with unstable income or living on the edge? They'll be paying a premium for this pill 
. Not cool, Novo Nordisk 
shouldn't we just focus on eating more veggies instead of trying to control our bodies with meds, you know? 
and 17% body weight loss in 64 weeks is crazy, but like, what about the long-term effects, right? 
don't we want to know if it's gonna lead to more health issues or something?
can't we just have one solution instead of two? 
! As someone who's struggled with weight loss for years, I can attest that taking a pill every day is way more convenient than having to give myself injections 
. And $25 a month sounds like a total steal for me 
. I'm planning on asking my doctor if I can get the prescription ASAP. Does anyone know when Wegovy will be available at pharmacies? 
. Anyway, I'm thinking of sharing this news with all my friends and family who are struggling with weight loss 
. It's like, finally a glimmer of hope for us! 
And can you believe Eli Lilly is working on a similar pill? That's just crazy talk 
!
Now it's all about swallowing pills twice a day or having to give your body a break for an hour after eating. It's like we're still learning how to deal with these newfangled meds. I mean, I'm not saying I wouldn't want to try Wegovy if it helps me get off this couch, but 30 minutes without food? That's just crazy talk! And don't even get me started on the prices - $25 a month for insured folks and over $200 a month for the rest of us? That's just not right. I guess progress is a slow and expensive thing... 
i just hope they dont make us take it every day or ill be one of those crazy pills-taking people again